None listed
Conditions
Interventions
Intervention1: Iodex Ultra gel, 0.042 gm
: Topical marketed product Iodex Ultragel containing Diclofenac 1.16%, Menthol 5%,
Methyl salicylate 10%
Twice daily application over a
period of 1 week
Contr
Sponsors
GSK Consumer Healthcare
Eligibility
Inclusion criteria
Inclusion criteria: 1. Healthy male or female volunteers aged atleast 18 years. 2. Good general, physical and mental health in the opinion of the investigator or medically qualified designee: a) No clinically significant and relevant abnormalities in medical history or upon physical examination. b) Absence of any condition that could affect the volunteerâ??s safety or wellbeing or their ability to understand and follow study procedures and requirements. 3. Healthy volunteers who do not have excessive hair on the volar aspect of the forearm(s). 4. Healthy volunteers should understand and be willing to fully comply with all study procedures and restrictions. 5. Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form. 6. Females of childbearing potential, using an effective contraceptive method for at least one month before the beginning of the study, and willing to use throughout the study.
Exclusion criteria
Exclusion criteria: 1. Volunteers having recent history (within one year) of alcohol or other substance abuse as determined by medical history. 2. Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit. 3. Previous participation in similar study with similar products. 4. Volunteer has any visible skin disease at the site of application that, in the opinion of the investigator, will interfere with the skin assessments. 5. Volunteer has current or relevant previous history of serious, severe or unstable physical or psychiatric illness, or medical disorders, such as current or previous history of hepatic or renal diseases (impairment) or peptic ulcer as determined by medical history. 6. Volunteer has a history of hypersensitivity (e.g. asthma, bronchospasm, rhinitis, urticaria, nasal polyps) to aspirin, diclofenac, other NSAIDs, menthol or any of the excipients in the test product(s). 7. Volunteer is receiving systemic or topical NSAIDs, other oral or topical analgesics or antihistamine within 3 days of visit 1, or other medication (such as corticosteroid within 3 weeks of visit 1) which, in the opinion of the investigative personnel, will interfere with the study results. 8. Female volunteers who are pregnant, planning to become pregnant during the study, or are breast-feeding. 9. Female volunteers who have positive pregnancy test. 10. Volunteers who are employees of the sponsor or study site or an immediate family member (e.g. partner, offspring, parents, siblings or siblingâ??s offspring) of such employees. 11. Any skin disorder at the test site that in the investigatorâ??s judgement can affect the readings of the test result 12. Any concomitant medications that in the investigatorâ??s judgement can confound or alter test results or evaluation of adverse events.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the skin irritation potential of topical analgesic Vovilup spray using clinical evaluation. o To compare the skin irritancy of topical analgesic Vovilup spray with that of an active control- Iodex Ultragel using clinical evaluation.Timepoint: Day0, Day1-6, Day7 | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare the skin irritation of topical analgesic Vovilup spray with that of negative control (0.9% Saline) using clinical evaluation.Timepoint: Day0, Day1-6, Day7 | — |
Countries
India
Contacts
Public ContactRashi Nangia
CIDP Biotech India Pvt Ltd
Outcome results
None listed